A diagnosis of ductal carcinoma in situ, or DCIS, often comes as a surprise during a routine mammogram. While the news is understandably taxing, it is important to remember that DCIS is a noninvasive, ...
Thomas Jefferson University biostatistician Terry Hyslop designed a trial showing active monitoring to be as effective as ...
SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer versus guideline-recommended treatment, the randomized COMET ...
There's a long-standing concern among oncologists that many women with ductal carcinoma in situ (DCIS), a potential precursor to invasive breast cancer, receive more treatment than they need. The ...
MedPage Today on MSN
Active surveillance for DCIS moves closer to standard option but not quite there
Large randomized trial makes case for non-inferiority versus surgery; smaller study falls ...
The hormone therapy tamoxifen can keep cancer from recurring in women with DCIS Tamoxifen following lumpectomy reduced risk of recurrence 44% to 51% Tamoxifen blocks estrogen receptors in cancer cells ...
Some early breast cancer patients can safely avoid specific surgeries, according to two studies exploring ways to lessen treatment burdens. One new study, published in the New England Journal of ...
A polygenic risk score (PRS) may help identify women who are at a greater risk of developing a future breast cancer after treatment for in situ breast disease, a retrospective study suggests. The ...
INSITE Trial included more than 400 patients at 14 leading academic and community cancer centers Intracavity visualization system uses fluorescence imaging designed to identify residual cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results